Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT05604560
Title A Neoadjuvant Study of Tislelizumab and SX-682 for Resectable Pancreas Cancer
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.